[HTML][HTML] The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification
Abstract The 2015 World Health Organization (WHO) Classification of Tumors of the Lung,
Pleura, Thymus and Heart has just been published with numerous important changes from …
Pleura, Thymus and Heart has just been published with numerous important changes from …
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met …
Purpose Non–small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and
its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical …
its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical …
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
Purpose To further understand the molecular pathogenesis of pulmonary sarcomatoid
carcinoma (PSC) and develop new therapeutic strategies in this treatment-refractory …
carcinoma (PSC) and develop new therapeutic strategies in this treatment-refractory …
[HTML][HTML] Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by …
AB Schrock, SD Li, GM Frampton, J Suh… - Journal of Thoracic …, 2017 - Elsevier
Introduction Pulmonary sarcomatoid carcinoma (PSC) is a high-grade NSCLC characterized
by poor prognosis and resistance to chemotherapy. Development of targeted therapeutic …
by poor prognosis and resistance to chemotherapy. Development of targeted therapeutic …
Multimodality treatment of pulmonary sarcomatoid carcinoma: a review of current state of art
L Zhang, W Lin, Z Yang, R Li, Y Gao… - Journal of Oncology, 2022 - Wiley Online Library
Pulmonary sarcomatoid carcinoma (PSC) is an unconventional non‐small‐cell lung cancer
(NSCLC) that is currently managed under guidelines used for conventional NSCLC and has …
(NSCLC) that is currently managed under guidelines used for conventional NSCLC and has …
[HTML][HTML] Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma
T Vieira, N Girard, M Ung, I Monnet, A Cazes… - Journal of Thoracic …, 2013 - Elsevier
Background: Sarcomatoid carcinomas (SCs) are rare tumors that may arise in the lung,
accounting for 0.4% of non–small-cell lung cancers; the prognosis is poor. Only few …
accounting for 0.4% of non–small-cell lung cancers; the prognosis is poor. Only few …
[HTML][HTML] Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages
T Vieira, M Antoine, C Hamard, V Fallet, M Duruisseaux… - Lung Cancer, 2016 - Elsevier
Objectives Pulmonary sarcomatoid carcinomas (SC) are rare tumors, associated with worse
prognosis and resistant to platinum-based regimens. Therapies targeting the PD-1/PD-L1 …
prognosis and resistant to platinum-based regimens. Therapies targeting the PD-1/PD-L1 …
Sarcomatoid carcinoma of the lung: the Mayo Clinic experience in 127 patients
K Maneenil, Z Xue, M Liu, J Boland, F Wu… - Clinical lung cancer, 2018 - Elsevier
Background Pulmonary sarcomatoid carcinoma (PSC) is an unusual form of non–small-cell
lung cancer (NSCLC). Because of its rarity and heterogeneity, the treatment and prognosis …
lung cancer (NSCLC). Because of its rarity and heterogeneity, the treatment and prognosis …
Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung
M Ung, I Rouquette, T Filleron, K Taillandy… - Clinical lung cancer, 2016 - Elsevier
Background Sarcomatoid carcinoma is a rare subtype of non–small-cell lung cancer, which
has aggressive behavior. We present information on the clinicopathologic characteristics …
has aggressive behavior. We present information on the clinicopathologic characteristics …
Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer with poor
prognosis. Here, we perform multi-omics analysis of 56 PSC samples, 14 of which are …
prognosis. Here, we perform multi-omics analysis of 56 PSC samples, 14 of which are …